Malignant pleural mesothelioma Header
opdivo-dtc-util-nav

Indications

Prescribing Information

Next Page Icon

Medication Guide

Next Page Icon
Potential OPDIVO® (nivolumab) user looking at her phone with her daughter.
Potential OPDIVO® (nivolumab) user looking at her phone with her daughter.

Clinical trial results for
malignant pleural
mesothelioma

For adults with previously untreated malignant pleural mesothelioma (MPM) that cannot be removed by surgery

Actor portrayals.

An FDA-approved combination of two immunotherapies that helped people live longer compared to platinum-based chemotherapy

About the clinical trial

In a clinical trial of 605 people with previously untreated malignant pleural mesothelioma, 303 people were given OPDIVO + YERVOY, and 302 people were given platinum-based chemotherapy.

People given OPDIVO + YERVOY lived longer compared to platinum-based chemotherapy at a minimum follow-up of 22 months

At 18 months, half the people given OPDIVO® +  YERVOY® were alive.
OPDIVO + YERVOY

Half the people were alive

At 14 months, half the people given platinum-based chemotherapy were alive.
Platinum-based chemotherapy

Half the people were alive

In the clinical trial, people given OPDIVO + YERVOY had a 26% lower risk of dying than those given platinum-based chemotherapy.

OPDIVO + YERVOY will not work for everyone. Individual results may vary.

Hands exploring how OPDIVO® (nivolumab) works and learning how this treatment may help fight cancer.

How treatment works

See how this treatment may help your body fight cancer

OPDIVO® (nivolumab) side effects.

Side effects

View side effects of treatment and learn how to manage them

Nurse monitoring a gentleman's infusion of OPDIVO® (nivolumab) immunotherapy treatment.

Getting an infusion

See your recommended treatment plan and what to expect from an infusion

For adults newly diagnosed with malignant pleural mesothelioma (MPM) that cannot be removed by surgery

OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) as a first treatment for adults with a type of cancer that affects the lining of the lungs and chest wall called malignant pleural mesothelioma which cannot be removed by surgery.

OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.

It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.

It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.